Tag Archives: Sarepta

December, 2018

August, 2018

June, 2018

December, 2017

June, 2017

January, 2017

June, 2016

April, 2016

  • 26 April

    FDA Panel Votes Against Sarepta’s Drug to Treat Duchenne Muscular Dystrophy

    CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 25, 2016– Sarepta Therapeutics, Inc.(NASDAQ:SRPT), a developer of innovative RNA-based therapeutics, today announced that the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Advisory Committee (PCNSC) met to review the new drug application (NDA) for eteplirsen as a treatment for Duchenne muscular dystrophy amenable to exon 51 …

February, 2016

January, 2016

  • 22 January

    Weather Delays FDA Advisory Committee Meeting of Sarepta’s DMD Candidate

    CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 20, 2016– Sarepta Therapeutics, Inc.(NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Advisory Committee meeting scheduled for Friday, January 22 has been postponed by the FDA due to an anticipated severe winter snowstorm …